Everolimus + Rituximab
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
CD20+, B-cell Lymphomas
Conditions
CD20+, B-cell Lymphomas, Mantle Cell Lymphoma, Non-Mantle Cell Low Grade B Cell Lymphomas (SLL/CLL), Transformed Lymphoma/DLBCL/PMBCL, Hodgkin's Disease, Gray Zone Lymphoma
Trial Timeline
Sep 1, 2012 → Aug 1, 2020
NCT ID
NCT01665768About Everolimus + Rituximab
Everolimus + Rituximab is a phase 2 stage product being developed by Novartis for CD20+, B-cell Lymphomas. The current trial status is completed. This product is registered under clinical trial identifier NCT01665768. Target conditions include CD20+, B-cell Lymphomas, Mantle Cell Lymphoma, Non-Mantle Cell Low Grade B Cell Lymphomas (SLL/CLL).
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01665768 | Phase 2 | Completed |
| NCT00869999 | Phase 2 | Completed |